Editorially Independent Content, Supported with Advertising from Genentech and Carl Zeiss Meditec

Reviewing the BOULEVARD Trial and RG7716

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Show Description +

Rishi P. Singh, MD; Arshad M. Khanani, MD, MA; and Nancy Holekamp, MD, discuss which clinical endpoints from the phase 2 BOULEVARD clinical trial are most meaningful to them.

Posted: 9/27/2018

Keywords:

Updates in Changing Treatment Paradigms for DR

Up Next in this Program

Name: Reviewing the BOULEVARD Trial and RG7716
Uploaded: 2018-09-27T10:03:00+00:00
Description: Rishi P. Singh, MD; Arshad M. Khanani, MD, MA; and Nancy Holekamp, MD, discuss which clinical endpoints from the phase 2 BOULEVARD clinical trial are most meaningful to them.

Think Outside the Box: Treatment Options for DR

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Updates in Changing Treatment Paradigms for DR

Translating Data for Educating Patients With DR

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Anti-VEGF for DR: Implications for Clinical Practice

Arshad M. Khanani, MD, Nancy Holekamp, MD

Changing Treatment Paradigms for DR: Reviewing the Data

Arshad M. Khanani, MD, Nancy Holekamp, MD

Reviewing the BOULEVARD Trial and RG7716

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Think Outside the Box: Treatment Options for DR

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Key Takeaways for Treating Patients With DR

Anti-VEGF Therapy for Patients With Proliferative and Nonproliferative Disease

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

How to Manage Patient Buy-In for Anti-VEGF Therapy

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

Take-Home Points From the BOULEVARD Trial

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

New Horizons for Treatment Options for DR

Nikolas J.S. London, MD, Rishi P. Singh, MD, Tarek S. Hassan, MD

Medical Management of DR: Case Discussions

Kiss Case: Anti-VEGF Agents in a Case of PDR

Caroline R. Baumal, MD, Charles C. Wykoff, MD, PhD, FACS, Szilard Kiss, MD

Chiang Case: Peripheral Neovascularization With PDR

Allen Chiang, MD, Charles C. Wykoff, MD, PhD, FACS, Joseph M. Coney, MD

Coney Cases: Laser Versus Anti-VEGF Treatment for Diabetic Patients

Allen Chiang, MD, Charles Fritch MD, Joseph M. Coney, MD

Baumal Case: How to Treat Active PDR Without DME

Back to All Videos

Reviewing the BOULEVARD Trial and RG7716

Arshad M. Khanani, MD, Nancy Holekamp, MD, Rishi P. Singh, MD

Rishi P. Singh, MD; Arshad M. Khanani, MD, MA; and Nancy Holekamp, MD, discuss which clinical endpoints from the phase 2 BOULEVARD clinical trial are most meaningful to them.

Posted: 9/27/2018

Keywords:

Updates in Changing Treatment Paradigms for DR

Please log in to leave a comment.

Editorial Feature:

Diabetic Retinopathy

Reviewing the BOULEVARD Trial and RG7716

Up Next in this Program

Updates in Changing Treatment Paradigms for DR

Key Takeaways for Treating Patients With DR

Medical Management of DR: Case Discussions

Reviewing the BOULEVARD Trial and RG7716